XNASGDTC
Market cap29mUSD
Dec 24, Last price
2.58USD
1D
8.86%
1Q
75.51%
IPO
-31.38%
Name
CytoMed Therapeutics Ltd
Chart & Performance
P/E
—
P/S
139.25
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
291k
-20.16%
Net income
-3m
L-2.98%
CFO
-3m
L+85.25%
Profile
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.
Valuation
Title SGD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 291 -20.16% | 364 219.67% | 114 91.43% | ||
Cost of revenue | 1,652 | 2,128 | 1,683 | ||
Unusual Expense (Income) | |||||
NOPBT | (1,361) | (1,764) | (1,569) | ||
NOPBT Margin | |||||
Operating Taxes | 2 | (72) | |||
Tax Rate | |||||
NOPAT | (1,361) | (1,766) | (1,497) | ||
Net income | (3,132) -2.98% | (3,228) 55.60% | (2,075) 6.81% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 11,307 | 1,223 | 2,000 | ||
BB yield | -21.71% | ||||
| Debt | |||||
Debt current | 40 | 3,744 | 2,704 | ||
Long-term debt | 414 | 490 | 578 | ||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | (8,689) | 2,415 | 496 | ||
| Cash flow | |||||
Cash from operating activities | (2,591) | (1,398) | (1,713) | ||
CAPEX | (474) | (582) | |||
Cash from investing activities | (473) | (824) | |||
Cash from financing activities | 8,275 | 969 | 4,173 | ||
FCF | (342) | (1,753) | (2,025) | ||
| Balance | |||||
Cash | 8,995 | 1,580 | 2,513 | ||
Long term investments | 148 | 239 | 273 | ||
Excess cash | 9,128 | 1,801 | 2,780 | ||
Stockholders' equity | 8,525 | 714 | 1,450 | ||
Invested Capital | 3,167 | 4,090 | 4,400 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 10,630 | 7,915 | 6,935 | ||
Price | 4.90 | ||||
Market cap | 52,089 | ||||
EV | 43,400 | ||||
EBITDA | (1,073) | (1,371) | (1,239) | ||
EV/EBITDA | |||||
Interest | 125 | 118 | |||
Interest/NOPBT | |||||